Circulating Free Tumor DNA—Highly Specific, Moderately Sensitive For EGFR Mutation Testing in Lung Cancer

Circulating Free Tumor DNA—Highly Specific, Moderately Sensitive For EGFR Mutation Testing in Lung Cancer

27/04/2015

GENEVA—An alternative way of testing for mutated EGFR in patients with advanced non-small cell lung cancer was validated in research presented at the European Lung Cancer Conference by Martin Reck MD

GENEVA—An alternative way of testing for mutated EGFR in patients with advanced non-small cell lung cancer was validated in research presented at the European Lung Cancer Conference by Martin Reck MD PhD from the department of thoracic oncology at the Lung Clinic Grosshansdorf near Hamburg, Germany. He discussed with Oncology Times reporter Peter Goodwin the sensitivity and specificity of a new test for circulating free tumor DNA—for use in patients for whom tissue samples are not available.